222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 310 / Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05383547 (ClinicalTrials.gov) | August 2, 2022 | 10/5/2022 | Bortezomib for Treating Glomerular Diseases | Prospective Observation of Bortezomib in the Treatment of Glomerular Diseases | Bortezomib;Glomerulonephritis;MN;MPGN;FSGS;IgA Nephropathy | Drug: Bortezomib | Ruijin Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 20 | N/A | China |